Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 10:59AM ET
2.38
Dollar change
-0.03
Percentage change
-1.24
%
Index- P/E- EPS (ttm)-0.76 Insider Own31.54% Shs Outstand59.43M Perf Week-2.46%
Market Cap147.20M Forward P/E- EPS next Y-0.43 Insider Trans0.00% Shs Float42.34M Perf Month25.93%
Income-45.44M PEG- EPS next Q-0.10 Inst Own11.69% Short Float5.06% Perf Quarter42.51%
Sales0.00M P/S- EPS this Y26.15% Inst Trans-1.46% Short Ratio29.25 Perf Half Y31.49%
Book/sh-0.86 P/B- EPS next Y10.42% ROA-208.11% Short Interest2.14M Perf Year19.60%
Cash/sh0.33 P/C7.23 EPS next 5Y- ROE- 52W Range1.28 - 2.48 Perf YTD43.37%
Dividend Est.- P/FCF- EPS past 5Y-5.96% ROI-442.62% 52W High-4.03% Beta0.85
Dividend TTM- Quick Ratio2.05 Sales past 5Y0.00% Gross Margin- 52W Low85.94% ATR (14)0.12
Dividend Ex-Date- Current Ratio2.05 EPS Y/Y TTM-27.74% Oper. Margin0.00% RSI (14)68.35 Volatility7.34% 6.10%
Employees12 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price11.00
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q-62.77% Payout- Rel Volume0.60 Prev Close2.41
Sales Surprise- EPS Surprise-140.00% Sales Q/Q- EarningsNov 13 BMO Avg Volume73.25K Price2.38
SMA2011.80% SMA5025.02% SMA20032.72% Trades Volume11,647 Change-1.24%
Date Action Analyst Rating Change Price Target Change
Aug-13-20Reiterated H.C. Wainwright Buy $9 → $12
Feb-13-19Initiated B. Riley FBR Buy $11
Dec-07-17Reiterated H.C. Wainwright Buy $6 → $10
Nov-28-17Reiterated H.C. Wainwright Buy $3.50 → $6
Oct-19-17Initiated ROTH Capital Buy
Mar-30-17Upgrade H.C. Wainwright Neutral → Buy $3.50
Oct-03-16Downgrade FBR & Co. Outperform → Mkt Perform $12 → $2
Sep-29-16Downgrade H.C. Wainwright Buy → Neutral $1.50
Sep-28-16Downgrade ROTH Capital Buy → Sell
Mar-28-16Resumed H.C. Wainwright Buy $8
Mar-12-24 08:00AM
Nov-13-23 11:11AM
08:45AM
08:00AM
Nov-03-23 08:00AM
08:00AM Loading…
Oct-23-23 08:00AM
Oct-12-23 08:00AM
Oct-03-23 08:00AM
Sep-26-23 08:00AM
Sep-13-23 05:22PM
Sep-11-23 09:55AM
08:00AM
Sep-07-23 12:00PM
Aug-17-23 12:00PM
Aug-14-23 08:00AM
04:37PM Loading…
May-18-23 04:37PM
May-15-23 08:00AM
Apr-27-23 08:00AM
Apr-18-23 08:00AM
Mar-30-23 08:00AM
Mar-16-23 08:00AM
Mar-02-23 08:00AM
Jan-24-23 08:00AM
Jan-05-23 08:00AM
Dec-13-22 09:55AM
Nov-29-22 08:00AM
Nov-28-22 08:00AM
Nov-14-22 08:00AM
Nov-01-22 08:00AM
Oct-14-22 08:00AM
08:00AM Loading…
Oct-12-22 08:00AM
Oct-06-22 08:00AM
Sep-08-22 08:00AM
Aug-15-22 08:00AM
Jul-26-22 08:00AM
Jun-21-22 08:00AM
May-23-22 08:00AM
May-16-22 08:00AM
May-11-22 11:20AM
May-03-22 08:30AM
Apr-15-22 07:20AM
Apr-14-22 08:00AM
Mar-31-22 08:00AM
Jan-06-22 08:00AM
Dec-21-21 08:00AM
Dec-13-21 08:00AM
Nov-15-21 08:00AM
Nov-05-21 04:24PM
Oct-27-21 08:00AM
Oct-05-21 03:39PM
01:55PM
Sep-21-21 08:00AM
Sep-09-21 09:00AM
Aug-30-21 08:00AM
Aug-16-21 09:00AM
Jul-30-21 04:28AM
Jul-09-21 09:25AM
08:00AM
06:29AM
Jun-13-21 11:23PM
May-17-21 08:00AM
Apr-27-21 09:28AM
Apr-19-21 08:00AM
Apr-15-21 09:00AM
Apr-14-21 08:28AM
Apr-13-21 07:01PM
Apr-06-21 08:00AM
Mar-31-21 08:00AM
Mar-08-21 08:00AM
Mar-04-21 08:00AM
Jan-31-21 02:28AM
Jan-19-21 11:15AM
Dec-11-20 08:00AM
Dec-04-20 04:17PM
Dec-01-20 08:00AM
Nov-09-20 08:00AM
Nov-02-20 08:02AM
Oct-12-20 08:11AM
Oct-06-20 03:30PM
Sep-29-20 12:00PM
08:52AM
Sep-22-20 08:04AM
Sep-10-20 08:00AM
Sep-09-20 11:46AM
Sep-02-20 08:00AM
Aug-10-20 08:00AM
Aug-03-20 12:48PM
Jun-30-20 09:05AM
08:00AM
Jun-04-20 09:48PM
May-22-20 08:17AM
May-11-20 08:00AM
May-04-20 08:37AM
Apr-30-20 09:00AM
Apr-02-20 08:04AM
Mar-16-20 08:00AM
Feb-20-20 08:00AM
Feb-05-20 04:11PM
Feb-04-20 08:04AM
08:00AM
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ELDRED KARYDirectorJan 16 '24Buy1.7950089349,313Jan 16 11:23 AM
Uihlein Richard EDirectorSep 26 '23Option Exercise4.492,236,20410,033,02010,235,495Sep 27 02:03 PM
ELDRED KARYDirectorJul 19 '23Buy1.791,5982,85448,813Jul 20 07:40 AM